Navigation Links
Enigma Diagnostics Announces Signing of Patent Licenses With Roche Molecular Systems, Inc.
Date:7/16/2009

PORTON DOWN, England, July 16 /PRNewswire/ -- Enigma Diagnostics Limited, the decentralized and point-of-care molecular diagnostics company, announced today that it has signed two patent license agreements with Roche Molecular Systems, Inc. (RMS).

The licenses signed on 15 July 2009, provide Enigma full access under patents owned or licensed by RMS and its affiliates to practice HybProbe real-time PCR chemistry and melt analysis and will allow Enigma to commercialize HybProbe PCR tests for human and veterinary in vitro diagnostics on a worldwide basis. The two licenses with RMS complement Enigma's existing patent portfolio as well as intellectual property licensed by Celera Diagnostics for real-time PCR thermal cyclers.

Enigma is currently developing a series of highly multiplexed, HybProbe assays for its infectious disease programs including pandemic and seasonal influenza, chlamydia and MRSA. These tests will be combined with Enigma's revolutionary fully automated real-time PCR system, the Enigma ML (mini-laboratory), enabling fast and accurate 'test and treat' molecular diagnostics at point-of-care.

Financial terms were not disclosed.

About Enigma Diagnostics Limited

Enigma Diagnostics Limited specialises in developing next generation rapid molecular diagnostic instrument platforms for decentralised and point-of-care settings.

Enigma's innovative and proprietary technology combines the speed and sensitivity of real-time PCR (polymerase chain reaction) with the simplicity needed for decentralized and point-of-care testing providing results from a raw sample in less than 60 minutes. The Company is targeting a number of multi-billion pound markets, core among which are the Clinical and high-value Applied Markets. Enigma's commercialization strategy is to maximize revenues from a continuous flow of market leading rapid diagnostic point-of care instrument and assay platforms, based on unique technologies and underpinned by its broad Intellectual Property portfolio. Enigma will partner with market leaders where global penetration of markets is required and where appropriate, will engage regional partners and build in-house sales and marketing capability to direct distribution of its products.

Enigma has an exclusive license from the Defence Science Technology Laboratory to a portfolio of patents, which represent over 15 years of UK Ministry of Defence funded Research. It also has licenses from Applied Biosystems and Celera Diagnostics for commercialization of real-time PCR instruments. Enigma's R&D activities have generated a portfolio of over 50 plus worldwide patent families dedicated to real-time PCR and wider molecular technologies. Many of these patents are granted across a range of core commercial territories including US, EU and Japan with more extensive filing and grants across a number of other key territories.

For more information visit www.enigmadiagnostics.com

    UK Contact:
    Enigma Diagnostics
    Deborah Cordingley
    deborah.cordingley@enigmadiagnostics.com
    +44 1980 590131

    US Contact:
    Richard Lewis Communications, Inc
    212-827-0020
    Andrew Mielach - Media
    amielach@rlcinc.com
    Cecelia Heer - Investors
    cheer@rlcinc.com


'/>"/>
SOURCE Enigma Diagnostics Limited
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Enigma Diagnostics Announces Patent On Real-Time Monitoring of Amplification Reactions Upheld In Entirety Following Opposition From BD at European Patent Office
2. New light shed on the enigma of salt intake and hypertension
3. The Marketing Enigma
4. Enigma Diagnostics Announces a Signed Term Sheet for Patent Licenses with Roche Molecular Systems, Inc.
5. Ridge Diagnostics Wins Growth-Promoting Loan From Biotech Center
6. Quest Diagnostics To Release Second Quarter Financial Results
7. Quest Diagnostics Earns Platinum Honor As Best Employer For Healthy Lifestyles
8. Frost & Sullivan: Self-Monitoring and POC Diabetes Tests Reveal Potential for Significant Growth, Boosting the European Diabetes Diagnostics Market
9. Quest Diagnostics HemoCue Subsidiary to Add U.S. Hospital Laboratory Connectivity to Its HemoCue 201 DM Point-of-Care Systems
10. Quest Diagnostics to Speak at the Jefferies 3rd Annual Healthcare Conference
11. Quest Diagnostics Announces Pricing of Tender Offer for Up to $200 Million Aggregate Principal Amount of Certain of its Outstanding Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... FL (PRWEB) , ... December 08, 2016 , ... Coppin ... business owners and families in and around the Cape Coral area, is embarking on ... Chapin Food Bank of Southwest Florida. , The Harry Chapin Food Bank of Southwest ...
(Date:12/8/2016)... Fort Payne, AL (PRWEB) , ... December 08, ... ... enterprise offering insurance and financial consulting services to residential and commercial clients in ... raise awareness and support for Nobis Works. , Since 1977, Nobis Works has ...
(Date:12/7/2016)... ... , ... DrugDev again demonstrated its dedication to reducing the administrative ... adopters completing EU-U.S. Privacy Shield Certification from the U.S. Department of Commerce. , ... the Atlantic with a mechanism to comply with EU data protection requirements when transferring ...
(Date:12/7/2016)... ... December 07, 2016 , ... "Today, MHA and ... comprehensive mental health systems reform legislation in more than fifty years. We applaud ... commitment of our elected officials to improving mental health services and supports in ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... drug in their bodies, a researcher at the Icahn School of Medicine at ... , The study found that when young children are exposed to secondhand marijuana ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... NEW YORK , Dec. 8, 2016 ... ... such as reducing loss of blood during surgeries, lowering the ... surgeries, and decreasing risks of SSIs. The patient warming systems ... and intravascular warming systems.These benefits in turn reduce the stay ...
(Date:12/8/2016)... Dec. 8, 2016 KEY FINDINGS ... grow in 2017-2023. Various reasons for growth of the ... higher incidences of chronic diseases, high recovery cost of ... services. Medical lifting sling refers to an assistive ... mobility. These slings connect to the lift and hold ...
(Date:12/8/2016)... LONDON , Dec. 8, 2016 ... diagnostics includes products and tests that are used ... grass, weed, peanuts, milk, or drugs etc. in ... developed by the immune system. The report on ... future prospects of the market. The report consists ...
Breaking Medicine Technology: